Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829) | ANNALS OF ONCOLOGY |